» Articles » PMID: 36172195

Synergistic Effects of Natural Products in Combination with Anticancer Agents in Prostate Cancer: A Scoping Review

Overview
Journal Front Pharmacol
Date 2022 Sep 29
PMID 36172195
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer is the second most common cancer in men and has the fourth highest mortality among men worldwide. Different combination therapies for cancer are being tested, and among them, the integration of natural products is increasing. This study reviews research on the combination of anticancer drugs and natural products for the treatment of prostate cancer and suggests future directions in this field. Articles were identified by searching the PubMed, Embase, and Cochrane Library databases. Search keywords included the following: "Antineoplastic agents," "Anticancer drug," "Phytotherapy," "Natural product," "Drug synergism," and "Synergistic effect". The selection process focused on whether the differences in efficacy of anticancer drugs were evaluated when combined with natural products. Nineteen studies were included. All 19 studies evaluated efficacy , as well as 10 . There were 13 studies on a single compound extracted from natural products, three studies on mushroom and herb extracts, and three studies on herbal medicines consisting of three herbs, and a dietary supplement containing 10 herbs. Cancer cell lines used were PC-3 in nine studies, LNCaP in six studies, C4-2 in five studies, DU-145 in four studies, and 22Rv1 in two studies. Anti-cancer drugs co-administered were as follows: docetaxel in nine studies, doxorubicin and enzalutamide in three studies, paclitaxel and suberoylanilide hydroxamic acid in two studies, and cisplatin, vincristine, and bicalutamide in one study each. Although prostate cancer is prevalent worldwide, there are relatively few studies on the use of natural products with anticancer agents as treatment. Since it has reported that the efficacy of anticancer drugs is enhanced by coadministration of natural products, it is necessary to conduct further studies on this.

Citing Articles

Synergistic attenuation of complete freund's adjuvant-induced inflammation in mice using shinbaro-pelubiprofen: a novel therapeutic complex.

Kim H, Hong J, Jeon W, Kim H, Yeo C, Lee J Mol Med. 2025; 31(1):17.

PMID: 39838308 PMC: 11753103. DOI: 10.1186/s10020-025-01083-y.


Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.

Rahman M, Akter K, Ahmed K, Maharub Hossain Fahim M, Aktary N, Park M Cancers (Basel). 2024; 16(16).

PMID: 39199550 PMC: 11352813. DOI: 10.3390/cancers16162777.


Prospects of compounds of herbal plants as anticancer agents: a comprehensive review from molecular pathways.

Situmorang P, Ilyas S, Nugraha S, Syahputra R, Nik Abd Rahman N Front Pharmacol. 2024; 15:1387866.

PMID: 39104398 PMC: 11298448. DOI: 10.3389/fphar.2024.1387866.


Alkaloid-Based Isoxazolylureas: Synthesis and Effect in Combination with Anticancer Drugs on C6 Rat Glioma Model Cells.

Mukusheva G, Jalmakhanbetova R, Shaibek A, Nurmaganbetova M, Zhasymbekova A, Nurkenov O Molecules. 2024; 29(14).

PMID: 39064825 PMC: 11278957. DOI: 10.3390/molecules29143246.


Solid Lipid Nanoparticles Based on Babassu Oil and Copaiba Oleoresin: A Promising Approach for Prostate Cancer Therapy.

da Silva M, Rodrigues A, Costa M, Camara A, Cabral L, Junior E Nanomaterials (Basel). 2024; 14(12).

PMID: 38921890 PMC: 11206491. DOI: 10.3390/nano14121014.


References
1.
Huang E, Zhao Y, Chen G, Baek S, McEntee M, Minkin S . Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells. BMC Complement Altern Med. 2014; 14:68. PMC: 3938081. DOI: 10.1186/1472-6882-14-68. View

2.
Kai L, Samuel S, Levenson A . Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer. 2009; 126(7):1538-48. DOI: 10.1002/ijc.24928. View

3.
Bayat Mokhtari R, Homayouni T, Baluch N, Morgatskaya E, Kumar S, Das B . Combination therapy in combating cancer. Oncotarget. 2017; 8(23):38022-38043. PMC: 5514969. DOI: 10.18632/oncotarget.16723. View

4.
Lin P, Aronson W, Freedland S . An update of research evidence on nutrition and prostate cancer. Urol Oncol. 2017; 37(6):387-401. DOI: 10.1016/j.urolonc.2017.10.006. View

5.
Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C . Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014; 8(2):311-22. PMC: 5528545. DOI: 10.1016/j.molonc.2013.12.004. View